A Phase 4 interventional study of Sayana Press in Contraception, sponsored by Pfizer. Completed at 28 sites in United Kingdom. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-18.
Sponsored by Pfizer · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A one-year evaluation of Sayana Press self injection in women of reproductive age in the United Kingdom (UK).
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single arm
Drug: Sayana Press
Sayana Press in the Uniject injection system
Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set)
Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by generalized estimating equation (GEE) model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% confidence interval (CI) for the intercept was transformed to a 95% CI for the self-injection success rate.
Time frame: Up to 1 year
Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Sensitivity Analysis)
Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by GEE model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% CI for the intercept was transformed to a 95% CI for the self-injection success rate. The sensitivity analysis was conducted to eliminate the data from the discontinued site due to ongoing Good Clinical Practice (GCP) violations.
Time frame: Up to 1 year
Continuation Rate for the Method (Self-injection With Sayana Press) at 1 Year
Continuation rate for the method at 1 year equals: (\[the number of participants who received all 4 injections and had not discontinued by 12 months\] / \[total number of participants in the study\]) \*100%. A 95% CI was calculated along with the continuation rate using normal approximation to the binominal.
Time frame: 1 year
| Milestone | Sayana Press |
|---|---|
| Started | 169 |
| Completed | 114 |
| Not completed | 55 |
| Withdrew: Withdrawal by subject | 10 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Not defined | 2 |
| Withdrew: Lost to follow-up | 19 |
| Withdrew: Adverse event | 22 |
| Withdrew: Medication error without associated ae | 1 |
Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by generalized estimating equation (GEE) model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% confidence interval (CI) for the intercept was transformed to a 95% CI for the self-injection success rate.
| Percentage of all attempts at home | Sayana Press |
|---|---|
| Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Full Analysis Set) | 88.8 (85.1 to 91.6) |
Each participant had a maximum of 3 home self-injections, each of which was defined as a success or failure. A success was defined as a home self-injection that was successfully performed by the participant at home and on schedule (13 week interval +/- 1 week) where all attempts were included in the denominator. If the participant attempted but was unable to administer the self-injection at home and had it performed instead at the clinic, then these were classed as failures. This outcome measure was analyzed by GEE model using participant as the clustering variable. The GEE model used the logit link and contained an intercept term. The 95% CI for the intercept was transformed to a 95% CI for the self-injection success rate. The sensitivity analysis was conducted to eliminate the data from the discontinued site due to ongoing Good Clinical Practice (GCP) violations.
| Percentage of all attempts at home | Sayana Press |
|---|---|
| Percentage of Successful Self-Injections Performed of All Attempts at Home on Schedule (Sensitivity Analysis) | 89.3 (85.6 to 92.1) |
Continuation rate for the method at 1 year equals: (\[the number of participants who received all 4 injections and had not discontinued by 12 months\] / \[total number of participants in the study\]) \*100%. A 95% CI was calculated along with the continuation rate using normal approximation to the binominal.
| Percentage of total participants | Sayana Press |
|---|---|
| Continuation Rate for the Method (Self-injection With Sayana Press) at 1 Year | 67.5 (59.8 to 74.5) |
Collected over Up to 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sayana Press | 0/169 (0%) | 5/169 (3%) | 60/169 (35.5%) |
| Event | Sayana Press |
|---|---|
| Food poisoningGastrointestinal disorders | 1/169 |
| MastitisInfections and infestations | 1/169 |
| Ovarian germ cell teratoma benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/169 |
| Cauda equina syndromeNervous system disorders | 1/169 |
| Cervical dysplasiaReproductive system and breast disorders | 1/169 |
| Event | Sayana Press |
|---|---|
| Injection site bruisingGeneral disorders | 22/169 |
| Vaginal haemorrhageReproductive system and breast disorders | 21/169 |
| DepressionPsychiatric disorders | 13/169 |
| Injection site painGeneral disorders | 11/169 |
| Injection site massGeneral disorders | 9/169 |
Baseline analysis population included all participants who enrolled into the study.
| Age, Continuous(Years) | Sayana Press |
|---|---|
| Mean | 29.1 ± 7.26 |
| Sex: Female, Male(Participants) | Sayana Press |
|---|---|
| Female | 169 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | Sayana Press |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 154 |
| Unknown or Not Reported | 15 |
| Race (NIH/OMB)(Participants) | Sayana Press |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 163 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Aug 2017 to primary completion in Dec 2018, 15 months.
Results were first posted in Oct 2019, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Medroxyprogesterone Acetate